Abstract
Objective This study aims to explore the causal relationship between 731 immune cell traits and vitiligo using Mendelian randomization.
Methods We used a two-sample Mendelian randomization (MR) analysis, employing genetic variations extracted from genome-wide association studies (GWAS) as instrumental variables (IVs). Data sources included immune phenotype data from 3,757 European individuals and data from FinnGen, comprising a total of 385,538 samples (292 cases and 385,509 controls). The study used the inverse-variance weighted (IVW) method as the primary analysis method and conducted various robustness tests through median-based weighted analysis, mode-based weighted analysis, and the MR-Egger method to control for false positive results in multiple hypothesis testing.
Results Our study found that the pathogenesis of vitiligo may significantly reduce the levels of the following immune cells: TD CD4+ %T cells (b=-0.458, 95% CI=0.17-0.76, PFDR=0.015, P=0.000), CD25 on CD39+ CD4+ cells (b=-0.155, 95% CI=0.78-0.94, PFDR=0.166, P=0.769), and CD4 on HLA DR+ CD4+ cells (b=-0.431, 95% CI=0.50-0.85, PFDR=0.166, P=0.001). Additionally, the causal effect estimate of vitiligo on CCR2 on monocyte is 0.75 (b=-0.290, 95% CI=0.64-0.88, PFDR=0.114, P=0.828), and a negative association was also found on FSC-A on NK cells (b=-0.481, 95% CI=0.47-0.82, PFDR=0.142, P=0.197). On the other hand, our study suggests that the occurrence of vitiligo may increase the levels of CD28 on CD28+ CD45RA+ CD8br cells (b=0.311, 95% CI=1.13-1.65, PFDR=0.166, P=0.393).
Conclusion The results of this study reveal causal links between vitiligo and multiple immune cell traits, highlighting the important role of the immune system in the pathogenesis of vitiligo. These findings provide new research directions for controlling vitiligo through immune regulation and may pave the way for early intervention and treatment strategies.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Yes
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The data for this study were obtained from publicly accessible databases, thereby eliminating the need for further ethical approval. The studies were conducted in accordance with the local legislation and institutional requirements. Written informed consent for participation was not required from the participants or the participants’ legal guardians/next of kin in accordance with the national legislation and institutional requirements.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data availability statement
The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding author.
